Logo
U

UroGen Pharma

262 employees

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

Investor insights

Funding rounds participated in

$108M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2004

Funding rounds raised

Total raised

$108M

from investors over 1 rounds

U

UroGen Pharma raised $108M on July 17, 2024

FAQ